- Home
- ACN vs GILD Comparison
ACN vs GILD Comparison
Compare ACN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACN
- GILD
- Stock Information
- Founded
- ACN 1989
- GILD 1987
- Country
- ACN Ireland
- GILD United States
- Employees
- ACN N/A
- GILD N/A
- Industry
- ACN Business Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACN Consumer Discretionary
- GILD Health Care
- Exchange
- ACN Nasdaq
- GILD Nasdaq
- Market Cap
- ACN 148.6B
- GILD 145.4B
- IPO Year
- ACN N/A
- GILD 1992
- Fundamental
- Price
- ACN $253.35
- GILD $117.88
- Analyst Decision
- ACN Buy
- GILD Buy
- Analyst Count
- ACN 22
- GILD 22
- Target Price
- ACN $298.82
- GILD $118.76
- AVG Volume (30 Days)
- ACN 4.1M
- GILD 7.3M
- Earning Date
- ACN 12-18-2025
- GILD 10-30-2025
- Dividend Yield
- ACN 2.57%
- GILD 2.68%
- EPS Growth
- ACN 6.28
- GILD 496.80
- EPS
- ACN 12.15
- GILD 5.01
- Revenue
- ACN $69,672,977,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- ACN $6.81
- GILD $2.25
- Revenue Next Year
- ACN $5.39
- GILD $3.77
- P/E Ratio
- ACN $20.85
- GILD $23.52
- Revenue Growth
- ACN 7.36
- GILD 3.81
- 52 Week Low
- ACN $229.40
- GILD $86.08
- 52 Week High
- ACN $398.35
- GILD $124.61
- Technical
- Relative Strength Index (RSI)
- ACN 58.35
- GILD 50.25
- Support Level
- ACN $245.44
- GILD $118.71
- Resistance Level
- ACN $252.09
- GILD $121.58
- Average True Range (ATR)
- ACN 5.94
- GILD 2.78
- MACD
- ACN 1.25
- GILD -0.07
- Stochastic Oscillator
- ACN 93.69
- GILD 23.61
About ACN Accenture plc (Ireland)
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).